Loxo Oncology is developing multiple small molecule therapeutics utilizing focused clinical development strategies in well-defined patient populations. Larotrectinib, the only selective TRK inhibitor currently in clinical development, is being evaluated in a global Phase II multi-center basket study in patients with solid tumors that harbor TRK gene fusions and a Phase I multi-center, open-label trial in pediatric patients with advanced solid or primary central nervous system (CNS) tumors. The company also has pre-clinical programs in development, through its collaboration with Array BioPharma, for RET, FGFR, and FLT3.